The Oncology team employs multimodal and multisystem approaches to comprehensively define the immune and tumor microenvironment across the plasma cell dyscrasia continuum of disease. This includes longitudinal studies conducted throughout the standard of care therapy regimen for multiple myeloma patients, as well as in cases of primary or relapsed plasmacytoma disease. The goal of these projects is to uncover the intricate communications between plasma cell dyscrasias and the immune and tumor microenvironment (TME). Such discoveries may shed light on novel therapeutic modalities for addressing relapsed multiple myeloma and extramedullary plasmacytomas that thrive in a supportive microenvironment and contribute to unfavorable patient outcomes.